SOURCE: West et al., 2010. Eicosapentaenoic acid reduces polyp number & size in familial adenomatous polyposis
For those of us who walk the wards of polyposis registries, the surgical management of Familial Adenomatous Polyposis (FAP) has long felt like a double-edged sword. While a prophylactic colectomy is life-saving, the decision to perform an ileorectal anastomosis (IRA) rather than a total proctocolectomy is often a compromise—a bid for better functional quality of life that leaves the patient with a rectal remnant under constant threat. We have spent years searching for a “medical scalpel” to assist our endoscopic surveillance, and the recent study by West et al. regarding Eicosapentaenoic acid (EPA) suggests we may have found a remarkably safe one.
The “Why Now?”: Beyond the Shadow of COX-2 Inhibition
The clinical landscape for FAP has been dominated by selective cyclo-oxygenase-2 (COX-2) inhibitors like celecoxib. While effective, the cardiovascular “black box” surrounding long-term COX-2 use has always made me hesitate, particularly when prescribing for younger patients who face decades of therapy. We have reached a point where the standard of care requires an alternative that matches the efficacy of NSAIDs without the systemic toxicity.
“While the efficacy of COX-2 inhibitors in reducing polyp burden is well-established, the long-term cardiovascular risk profile has remained a significant barrier. We have been waiting for a metabolic approach that aligns with patient safety over a lifetime of use.”
The Surprise: Potency in a Free Fatty Acid Form
What I find most compelling about the West et al. data is the use of a specific, enteric-coated free fatty acid formulation (EPA-FFA). Many of my patients already experiment with over-the-counter fish oils, often with disappointing results due to poor absorption or the “fishy” dyspepsia that leads to non-compliance.
The trial demonstrated a 22.4% reduction in polyp number and a 29.8% decrease in the sum of polyp diameters over just six months. Interestingly, when you look at the “net change” compared to placebo, the magnitude of effect is strikingly similar to what we saw in the landmark Steinbach celecoxib trials. To achieve this with a naturally occurring fatty acid—one that actually carries cardiovascular benefits rather than risks—is a significant pivot for the field.
Mechanical Nuance and Mucosal Reality
The study wasn’t just a numbers game; it provided fascinating insight into the “mucosal reality” of EPA. We saw a 2.6-fold increase in mucosal EPA levels, yet, unexpectedly, this did not significantly displace arachidonic acid (AA).
“The data suggests we aren’t just diluting the ‘bad’ fats; we are fundamentally altering the mucosal environment. The fact that EPA can achieve these results without a significant drop in AA levels hints at complex, perhaps COX-independent, pathways that we are only beginning to understand.”
Practice Change: How I’m Talking to Patients Today
How does this change our Monday morning clinic? In my experience, EPA-FFA should now be discussed as a viable adjunct for any FAP patient with a retained rectum who is struggling with a rising polyp count.
- Tolerability is the Key: Unlike traditional NSAIDs, the adverse event profile was nearly identical to placebo, with the exception of some mild nausea. For the post-colectomy patient who already deals with increased bowel frequency, adding a medication that doesn’t exacerbate GI distress is a major win.
- The “Net” Effect: It is worth noting that while polyps in the active group regressed, the placebo group significantly worsened. This reminds us that in FAP, “staying the same” is often a victory.
“In my experience, the conversation with FAP patients is shifting. We are moving away from ‘how much risk can you tolerate’ to ‘how can we optimize your mucosal health.’ EPA-FFA fits perfectly into that new paradigm.”
Looking Ahead
While this study focused on the rectum, the obvious next step is exploring EPA’s effect on duodenal polyposis, which remains the leading cause of cancer death in post-colectomy FAP patients. If EPA can bridge the gap between surveillance and surgery in the upper GI tract as well, it will become a cornerstone of our toolkit.
For now, the message to our peers is clear: We have a new, safe, and effective intervention that respects the delicate balance of the FAP patient’s long-term health. It’s time we start using it.